CTA-Sticky-button.png clinicaltrialsyearbook+button

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player


ctsnordics2018-header.jpg

AstraZeneca discusses how scientific data and a risk-based distribution strategy can lower the risk of temperature excursions

The conference opened with a presentation from Eva-Lotta Persson, Supply Chain Programme Manager at AstraZeneca, in which she highlighted how scientific data and a risk-based distribution strategy can lower the risk of temperature excursions and avoid wasted product within the clinical supply chain. The presentation began by summing up that Good Distribution Practice was about making sure the correct product of the correct quality reaches the patient on time. Then, Eva-Lotta went into detail about what the biopharma industry needed to comply with in regards to current EU GDP Guidelines.

Another important, but often overlooked, question was answered: why do we need to generate stability data? It is easy for many companies to feel that regulatory requirements are the only reason but the presentation drew attention to how stability data not only secures safety and efficacy of the product but can also reduce cost by increasing the flexibility of IMP shipping.

The presentation then gave audience an insider-look at AstraZeneca’s venture into risk-based distribution practices. The outcomes were used to create a new distribution strategy based on compliance, simplicity, cost, environmental considerations and innovation.

For more innovative case studies, join us for our 2017 Clinical Trial Supply Nordics event.

Countdown to Clinical Trial Supply Nordics 2018






300x250-Subscribe-for-updates-banner+version+2.jpg